NCT06512389

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Centre for Addiction and Mental Health · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

Detailed description

Participants with alcohol use disorder will receive treatment daily (600mg cannabidiol or placebo), each for 10 consecutive days, with a 2-week long washout period between treatments. Participants will be randomized to receive placebo or cannabidiol first (in blocks of random size) so that equal number of participants are allocated to each sequence. Around day 8 of each treatment period, participants will complete an alcohol self-administration session in the laboratory to assess the effects of treatment on alcohol consumption and alcohol-related craving.

Conditions

• Alcohol Use Disorder

Interventions

Type	Name	Description
DRUG	Oral solution	300 mg taken morning and evening

Timeline

• Start date: 2024-08-16
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2024-07-22
• Last updated: 2026-03-20

Locations

1 site across 1 country: Canada